Engineering approaches for RNA-based and cell-based osteoarthritis therapies.
DeJulius CR, Walton BL, Colazo JM, d'Arcy R, Francini N, Brunger JM, Duvall CL.
DeJulius CR, et al. Among authors: walton bl.
Nat Rev Rheumatol. 2024 Feb;20(2):81-100. doi: 10.1038/s41584-023-01067-4. Epub 2024 Jan 22.
Nat Rev Rheumatol. 2024.
PMID: 38253889
Review.
However, the pharmacological therapies available remain limited, owing to drug delivery barriers, and consist mainly of broadly immunosuppressive regimens, such as corticosteroids, that provide only short-term palliative benefits and do not alter disease progression. Engin …
However, the pharmacological therapies available remain limited, owing to drug delivery barriers, and consist mainly of broadly immunosuppre …